MSK-2 Flashcards
Elderly patient bones:
* What decreases in bone?
* What is the most common fractures?
- Mineral content decreases
- Less water content in cartilage
- Connective tissues lose elasticity
- The most common fractures in the elderly osteoporotic patients in the chart
What is an important assessment in the aging patient
Monitoring for Height Changes via the spinal column
Elderly patient muscles:
* What happens and what accelerates it?
* What decreases (3)?
* What declines in efficiency?
* What slows down?
* What increases?
- Shrink and lose mass – as sedentary life accelerates
- # and size of muscle fibers decrease
- Water content of tendons decreases
- Handgrip strength decreases
- Heart muscle declines in efficiency
- Metabolism slows
- Lipids increase
How do you counteract the process of muscle wasting in elderly patients?
- Many of these changes result from disuse
- The most sedentary group in US is >50
- Exercise (weight-resistant specifically) and stretching is key
Sacropenia:
* What is sacropenia?
* what is it?
* What are the precentages?
* What does it correspond with?
* What tightens?
* What is replaced with adipose tissue?
- Age related decrease in muscles
- Estimates of 22% for women and 23% for men between the ages of 30-70, with strength loss of 30%
- Corresponding loss in balance and coordination
- Joint capsules tighten and lose flexibility
- Lean muscle mass replaced by adipose tissue
Cannot do ADLs so neeed to ensure muscle is okay
What is going on with these images?
- Increase adipose and decrease muscle
- Major health concern affecting 25% of people younger than 70 years and 40% of those 80 years and older
- Healthcare related costs – 18. 5 Billion in 2000 (NIH, 2011)
- What is the treatment for increase adipose and decrease muscle?
- What did Tufts university study revealed?
- What did a New Zealand study reveal?
- Resistance strength training even in the very aged and frail
- A Tufts University study revealed a 43% decrease in arthritic knee pain along with increased strength, decreased disability and general physical performance after a 16 week program of strength training
- A New Zealand study revealed a 40% reduction in falls (Women > 80)
- The effects of aging on the musculoskeletal system may be counteracted, to a degree, with what?
- All seniors, regardless of disability should have what?
- What should you not assume about geriatric pain?
- The effects of aging on the musculoskeletal system may be counteracted, to a degree, with exercise – specifically weight/resistance training.
- All seniors, regardless of disability should have some sort of exercise built into treatment plan
- Don’t assume all geriatric pain is osteoarthritis! (if they are losing height then check the spine)
Osteoporosis:
* What is it?
* What decreases?
* What is there a greater chance of?
- Abnormal bone remodeling disease.
- Decreased in total bone volume. Bone is less dense as you get older.
- Greater chance of fractures
What is the difference between osteopenia and osteoporosis?
Osteoporosis:
* What varys with age?
* How much do men and women need?
Calcium need vary with age and gender BUT need to be careful giving out supplements (ex. CHD and kidney disease)
* Women 51-70 need 1200mg/day
* Men 51-70 need 1000mg/day (a little less because not as estrogen dependent)
* Men and Women >70 need 1,200/day
Epidemiology of osteoporosis:
* When is low bone mass more common? What might it be related to?
* What may lead to an increase risk fracture?
- Low bone mass is more common in postmenopausal women and, when present, may be related to either inadequate peak bone mass acquisition, or previous or continuing bone loss.
- The clinical significance of isolated low bone density (without fracture) in young women is unknown. Some premenopausal women with low bone mineral density (BMD), particularly those with a known secondary cause of osteoporosis, may have abnormal bone strength that may lead to an increased risk of fracture.
Patho fracture, menopause, osteopenia= you need to look at bone den scan
What are the two types of primary osteoporosis?
Primary Osteoporosis (more common form) most
* Type 1 – Postmenopausal – due to decrease in estrogen or testosterone
* Type 2 – Senile – Inability to produce adequate Vit. D3 resulting in decreased
bone formation
What is secondary osteoporosis?
Secondary Osteoporosis (when other disease conditions predispose
to bone loss)
* Medications
* HyperPTH (more calcium in blood than bone)
* Excess ETOH use
* Smoking
Osteoporosis:
What are the typical symptoms and signs?
Typical symptoms:
* Back pain, loss of height, spinal deformities and protruding abdomen (dt lordosis and kyphosis)
Typical Signs:
* T score <-2.5 or FRAX >3% for hip fractures or >20% for major osteoporotic fx
What might be detected in x-ray with osteoporosis?
Bone Density Deficiency May Be Detected on X-ray (osteopenia), but Not diagnosed because you need a dexa scan
What is the dexa t-scores for diagnosis of osteoporosis?
What is the fracture risk assessment tool (FRAX)?
- The FRAX® tool has been developed to evaluate fracture risk of patients. It is based on individual patient models that integrate the risks associated with clinical risk factors as well as bone mineral density (BMD) at the femoral neck.
- The FRAX® algorithms give the 10-year probability of fracture. The output is a 10-year probability of hip fracture and the 10-year probability of a major osteoporotic fracture (clinical spine, forearm, hip or shoulder fracture)
ex. get a 2.2 for t scale so do a frax test to help educate
What is the treatment of osteoporosis?
- Weight-bearing exercises with resistance training
- Calcium, Vitamin D, and Phosphorus
- No Smoking
- Limited ETOH
- Bisphosphonates-Alendronate (Fosamax)
* Osteonecrosis of jaw (SE) - HRT
- SERMS
- PTH analog meds (teriparatide)-> for hyperparathyriod
What is osteoarthritis?
Degenerative disease
* overuse problem
* genetic or no genetic
* 70-80 year olds
OA Epidemiology:
* How many people are affected by OA?
* Women vs men?
* Who has a higher prevalence and severity of OA?
- Globally, approximately 300 million people are affected by hip and knee OA, including over 32 million in the United States, which has increased from 21 million in 1990 and 27 million in 2010.
- Worldwide estimates are that 10 percent of men and 18 percent of women aged over 60 years have symptomatic OA
- Female gender is associated with a higher prevalence and severity of OA.
- What is the strongest predictor of OA?
- What are the possible causes?
- Age is one of the strongest predictors of OA, with incidence of hand, hip, and knee OA increasing with age, especially after the age of 50 years.
- Possible causes are sarcopenia, loss of proprioception, and joint laxity that may affect joint function and predispose the joint to injury. Changes affecting joint tissues include loss of normal bone structure, increased stiffness of ligaments and tendons, and meniscal degeneration.
What is primary and secondary classification of OA?
Primary (idiopathic)
* No underlying cause apparent
Secondary
* Predisposing factor present - trauma, repetitive stress (occupation, sports),
congenital abnormality, metabolic disorder, or bone/joint disease
- What are the primary symptoms of osteoarthritis (OA)?
- Where do you they usally present?
- What bones are most likely affected?
- The primary symptoms of osteoarthritis (OA) are joint pain, stiffness lasting < 1 hour, crepitus, no systemic symptoms and locomotor restriction. ( not a systemic issue like fever, inflammation)
- They usually present in just one or a few joints in a middle-aged or older person.
- Hand DIP/PIP are most likely affected
* MCP joints except thumb (1st CMC) are spared
RA is most likey to be bilateral
OA:
* What type of patients?
- Older patients
- F>M
- Asymmetric
OA:
* What are the nodes of DIP and PIP called?
* What are the diagnostic levels?
* What are other issues?
- What are non-pharm txt of OA?
- Pharmacological txt?
- What is the last resort?
- Weight reduction, moderate physical activity, NSAIDs, intra-articular steroids, bracing, canes, and muscle-strengthening exercises
- Acetaminophen vs NSAIDs (depends on risk factors, but NSAIDs are preferred)
- Intraarticular glucocorticoid injections provide symptomatic relief but do infrequently as cartilage breakdown may be accelerated if performed too often
* Systemic glucocorticoids have no place in Rx of OA (RA might get this) - Surgery last resort
NSAIDs: kideney clearance so be careful with diabetes, HTN, and kidney disease
Fill in
- OA – assymetrical, weight bearing, NO redness or heat, Pain gets worse as day goes on and is alleviated by rest.
- RA – symmetrical (PIP/MCP), worse in AM and gets better as day goes on.
Epidemiology of RA:
* What is the prevalence worldwide?
* What is the prevalence and northern european countries?
* How many people are affected?
- The worldwide prevalence of RA has been estimated as 0.24 percent based upon the Global Burden of Disease 2010 Study.
- Estimates of RA prevalence in the United States and northern European countries are typically higher, usually between 0.5 to 1
percent dt auntoimmune, diet - The annual incidence of RA in the United States and northern European countries is estimated to be approximately 40 per 100,000 persons (also undiagnosised)
What is RA? What are the causes?
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by an inflammatory polyarthritis that preferentially affects the small joints.
- RA is a “multicausal” disease that most likely results from a combination of genetic predisposition and various environmental and lifestyle factors. Articular and systemic manifestations in RA can lead to poor long-term outcomes such as disability and death
What are RA clinical presentation?
- MCP joints are involved, others are spared.
- Joint pain and deformity
- Muscle weakness, myositis, osteopenia, and osteoporosis
- Extra-articular manifestations include changes in skin, lungs, kidneys, eyes, liver, blood system, and heart-> pul hem, chronic kidney disease, rash, eye issue
What are the clinical symptoms of RA (articular manifestations)
Symmetric polyarthritis involving small joints, may start as simple inflammation or synovitis, will progress to bone/cartilage erosions
What are the extra articular manifestations of RA?
- General: Fatigue, fever, weight loss
- Derm: Nodules
- Heme: Anemia (Felty’s Syndrome)
- Pulmonary: pleuritis/pneumonitis
- Cardiac: Peri or myocarditis and higher chance of having DVT (has autoimmune then need high awareness)
- Renal: Interstitial nephritis
- Ophthalmic: Episcleritis
- GI: Xerostomia
- MS: myositis
What is the cervical spine involvement of RA?
- Common at C1-C2, but remainder of spine is usually spared
- Instability of C spine is a life threatening complication of RA.
- InstabilityresultsfromacervicalligamentsynovitisinregionofC1-C2. * Occurs in 30-40% of pts who develop RA
- 5% of these eventually develop a myelopathy or cord injury
Issue since breathing is C4 so anything above-> DEAD
RA Diagnosis/Imaging:
* What needs to be quantified?
* What are the diagnosisic levels?
* What may be seen on x-ray?
* What may be evident?
What is the diagnostic criteria for RA?
A score ≥ 6 is needed for classification of a patient as having definite RA
What is the treatment of RA?
Consult with rheumatology
* PT/OT
* Pharm tx early and aggressive to reduce pain, preserve function, and prevent deformity
* NSAIDs with DMARDs (usually started together)
* DMARDs-initially methotrexate
What are the other DMARDs and newer biologic DMARDs for RA?
- Others DMARDs are steroids, sulfasalazine, antimalarials (hydroxychloroquine), and leflunomide.
- Newer biologic DMARDs are etanercept, abatacept, rituximab, infliximab, and adalimumab
What is felty’s syndrome?
Felty’s syndrome which usually occurs late in the disease process is manifested by splenomegaly, neutropenia, & + RA factor.
What is caplan’s syndrome?
Pulmonary-nodules, interstitial disease, pleural disease, Caplan’s syndrome [sero(+) RA associated with pneumoconiosis]
* Sero (+) that of CRP or RF
What is Juvenile idiopathic arthritis?
JIA Epidemiology:
* Who does it affects?
* What is the incidence?
* What is the prevalence?
* What is the female to male ratio?
- Affects all races and geographical locations
- Incidence: 6-20 cases per 100,000 children
- Prevalence: 16-150 per 100,000
- Females to Males ratio: 2>1
JIA etiology:
* What is the exact cause?
* What type of disease is it?
* What is happening in JIA to cause the disease? (MOA)
* What needs to be ruled out before JIA diagnosis?
- Exact Causes of JIA – UNKNOWN
- Is Autoimmune disease – body attacks itself
- In JIA, the synovial membrane is recognized by own immune system as a “foreign” invader, which causes immunologic attack in attempt to kill the tissue, hence the inflammatory process.
- Infection (septic arthritis), cancer, bone disease, Lyme disease and lupus must be ruled out before making a JIA/JRA diagnosis
What are the signs and symptoms of JIA (articular and extra-articular)
Diagnosis Criteria of JIA:
* Age?
* Duration of disease?
* What happens to the joints?
* What is the exclusion of?
- Age of Onset <16yo
- Duration of Disease >6 weeks
- Arthritis (swelling or effusion, limited ROM, tn or pain, increased warmth) in one or more joints
- Exclusion of other forms of arthritis
What are the different types of disease defined in the first 6 months with JIA?
Type of disease defined in the first 6 months:
* Polyarticular: 5 or more inflamed joints
* Oligoarticular: less than 5 inflamed joints
* Systemic arthritis with presence of fever
JIA treatment:
* What is preferred?
* What other therapies are there?
* What do you need to monitor for?
- DMARDs preferred over NSAIDs (2019 ACR guideline)
* Methotrexate preferred, Alt: Leflunomide or sulfasalazine
* MTX requires CBC (pancytopenia) and LFT monitoring (cirrhosis and hepatitis) - PT/OT
- Anakinra, TNFs, or abatcept for intractable cases
- Monitor for growth abnormalities, nutritional deficiencies and school/social impairment.
JIA:
* Who has a poorer prognosis than other children do?
Children with systemic JIA who fail to respond adequately to therapy have a significantly poorer prognosis than do children who achieve disease control.
Fibromyalgia Epidemiology:
* What is it?
* What is the prevalence?
* What was it initally termed? More common in who?
- Fibromyalgia (FM) is a common cause of chronic pain and the most common cause of generalized, musculoskeletal pain in women between ages of 20 and 55 years
- Prevalence is 2-3 percent and increases with age.
- Initially termed fibrositis, FM is more common in women than men and occurs in both children and adults. It is six times more common in women
The diagnosis may be under-recognized in clinical practice according to some sources, others indicate that those that are diagnosed, only half meet the actual criteria.
Fibromyalgia Etiology:
* What are the issues?
- Alterations in CNS pain processing patterns
- Sleep, mood, stress and cognitive disturbances.
- Genetics and environment
What are the different clinical presentations of FM?
Fibromyalgia:
* What do you need to rule out?
* How was it previously diagnosed?
- Rule out Differential diagnosis (Hypothyroidism, Hep C, Vitamin D deficiency, inflammatory processes)
- No specific tests, previously was diagnosed using tender point counting, no longer validated
* Generalized pain and tenderness, especially if disproportionate to physical findings
* Negative laboratory results despite widespread symptoms
* Fatigue as a predominant symptom - Clinical diagnosis-> rule out everything before FM
What is the treatment of FM?
What is the prognosis for FM?
- Chronic issue
- Waves often-> pain up and down
Polymyositis (PM) & Dermatomyositis (DM):
* What is it?
* What is it when skin is affected?
* What are other organs?
- Inflammatory CTD of WBC’s attacking healthy striated muscle
affecting the proximal limbs, neck, pharynx. - Skin can be affected = dermatomyositis
- Other organs - heart, joints, lungs, and GI tract
Polymyositis (PM) & Dermatomyositis (DM):
* Association of malignancy with dermatomyositis suggests what?
* Symmetrical weakness & pain causes what?
- Association of malignancy with dermatomyositis suggests that a tumor may incite myositis as result of an autoimmune reaction directed against a common antigen in muscle & tumor
- Symmetrical weakness & pain cause classic complaint of difficulty rising from a chair. Patients may eventually have difficulty breathing or swallowing
Tissue is replaced by scar tissue= decrease fxn
PM/DM Epidemiology:
* How many people are affected?
* The incidence of DM is higher in who?
* What is the annual incidence of PM?
- Dermatomyositis (DM) and polymyositis (PM) are relatively uncommon disorders. In a population-based study of the residents of Olmsted County in Minnesota that incorporated data from 1976 to 2007, the estimated annual incidence of all subtypes of DM was approximately 1 per 100,000 persons.
- The incidence of DM is higher in females compared with males. In the population-based study from Olmsted County, 22 of the 29 patients (76 percent) with DM were female. Individuals of any age can be affected.
- The annual incidence of PM has been reported to be 0.41 to 0.75 per 100,000 persons
What is the clinical presentation?
- The cardinal manifestation of dermatomyositis (DM) and polymyositis (PM) is gradual skeletal muscle weakness (usually painless), specifically symmetric proximal>distal muscle weakness.
* Muscle weakness may start suddenly & progress over weeks to months
* Difficulty raising their arms above shoulders, climbing steps or arising from a sitting position
* Flexors of neck may be severely affected, causing an inability to raise head from pillow - Dysphagia
- Malar skin rash
- Polyarthralgias (less pronounced than weakness)
- Muscle atrophy
What is the DM clinical presentation?
- Heliotrope rash (be careful-> similar to lupus)
- Reddish-violaceous eruption on upper eyelids, often accompanied by swelling of eyelid
- Symmetric, erythematous to purplish, scaly, flat papules on extensor surfaces of metacarpophalangeal & interphalangeal joints)
Low yield
What are the classfication of PM and DM?
What is the labs for PM/DM diagnosis? What else should be preformed?
- ESR, CPK and aldolase levels are elevated
- ANA may be positive
- Autoantibodies—anti-Jo-1 seen in 50% of pts with PM/15% with DM
- Muscle biopsy should be performed and will show inflammatory changes
What is the treatment plan for PM/DM (4 steps)?
- Step 1-Glucocorticosteroids-Prednisone 1mg/kg/d for 3-4 weeks, then tapered very gradually
- Step 2- Azathioprine or methotrexate
- Step 3 IV immunoglobulin over 2-5 days
- Step 4- Cyclosporine, chlorambucil, cyclophosphamide, or mycophenolate
Prognosis of PM/DM:
* What is the survival rate?
* What is mortality is often associated with?
* What is present in 305 of patients?
* What will have 5% of DM have?
- 5-year Survival is >80%
- Mortality is often associated with increased chance of malignancy and CV complications
- Residual weakness is present in 30% of patients following resolution
- Those with DM, 5% of them will have fulminant progression leading to death-> No treatment works
What are the symptoms/signs of Polymyalgia rheumatica (PMR)
PMR Epidemiology:
* Polymyalgia rheumatica (PMR) is almost exclusively a disease of adults over what?
* What is the prevalence of the disease?
* Who is more affected?
- Polymyalgia rheumatica (PMR) is almost exclusively a disease of adults over the age of 50, with a prevalence that increases progressively with advancing age. The peak incidence of PMR occurs between ages 70 and 80.
- PMR is relatively common. The lifetime risk of developing PMR has been estimated at 2.43 percent for women and 1.66 percent for men and is second only to rheumatoid arthritis (RA) as a systemic rheumatic disease in adults.
- Women are affected two to three times more often than men. Cases of familial aggregation are recognized
What is the big association with patients with PMR?
- Big association with patients having Giant Cell Arteritis (GCA)
PMR:
* What are the clinical presentation?
* What are the labs?
* When does it occur?
* Can occur in assoication with what?
- Clinical syndrome characterized by aching & morning stiffness in the shoulder girdle, hip girdle, or neck for > 1 month
- Elevated ESR, & rapid response to low-dose prednisone (15mg qd)
- Rarely occurs before age 50
- Can occur in association with giant cell arteritis, which requires treatment with higher doses of prednisone
What are other diagnosis/imaging needed for PMR?
ESR levels are markedly elevated. Temporal artery biopsy if suspected GCA.
* Labs to R/O other disorders (RF, ANA,CBC, CPK, SPEP)
* Renal, hepatic, & thyroid function tests
PMR treatment:
* What is it?
* What is the average length of disease?
* When can the disease recur?
- Primarily Low vs high-dose corticosteroids. Usually up to 2 years and slowly tapered.
- Average length of disease is 3 years
- Can recur if steroids are tapered too quickly
Sjogren Epidemiology:
* What does the estimates of SS depend on?
* How many people are affected?
- Estimates of the incidence and prevalence of Sjögren’s syndrome (SS) vary widely, depending upon the specific classification criteria, study design, and the population examined.
- Only a small minority (approximately 10 percent) of patients with clinically significant dry eye have SS.
What are the clinical manifestations of Sjogren?
- Constituional- fatigue
- Sicca symptoms- keratoconjunctivits sicca (KCS) & xerostomia
- Dryness of other surfaces-nose, vagina, trachea, skin
- Extraglandular features- arthralgia/arthritis, Raynaud’s, lymphadenopathy, interstitial pneumonitis, vasculitis (usually cutaneous), nephritis, lymphoma
Sjogren’s diagnosis:
* What is the criteria?
* What is considered necessary?
- Criteria: keratoconjunctivits sicca (KCS) xerostomia, (+) serologic features of autoimmunity
- Postive ANA, Anti SSA/Ro, anti SSB/La
- Positive lip biopsy considered necessary in some series-should be performed in setting of objective KCS/xerostomia with negative serologies
Sjogren:
* What are the lab levels?
* What biopsy needs to be done?
* What test?
* What does labial salivary gland biopsy show?
- RF is present in over 70%
- ANA in 60%
- Anti-Ro (SS-A) antibodies in 60%
- Anti-La (SS-B) antibodies in 40%
- Biopsy of lower lip mucosa confirms gland fibrosis and lymphocytic infiltrate (if negative above)
- Schirmer test (tear production)
- Labial salivary gland biopsy-demonstrates lymphocytic infiltration and destruction of glandular tissue
What is the schirmer test?
- Small strip of paper applied in conjunctival sac (lower eyelid) and eyes closed for 5 minutes.
- Moisture is measured after 5 minutes
* <5mm in 5 minutes is diagnostic for Sjogren’s syndrome
What is the Sjogren’s treatment
What is primary and secondary sjogren?
- Primary Sjogren: Usually good, unless severe extraglandular
manifestations develop
* Pediatric patients often do not develop sicca symptoms, therefore often do not seek care until more severe symptoms develop (eye irritation, dental caries, dyspareunia) - Secondary Sjogren: depends on primary autoimmune disorder
What is scleroderma aka systemic sclerosis?
SS epidemiology:
* What is the female to male ratop?
* What is the peak age?
* How many people affected?
- Female to male 4:1
- Peak age is between 30-50 years
- 2.5 million people-worldwide
SS Etiology:
* What is the cause?
* What is the chronic and rare?
* What does it involve?
* Antibodies are produced to what?
- Unknown cause and characterized by deposition of collagen in the skin and less commonly heart, kidney, lungs and stomach.
- Chronic and rare autoimmune systemic vascular and connective tissue disease
- Involves immunologic mechanisms leading to vascular endothelial damage & activation of fibroblasts
- Antibodies are produced to deoxyribonucleoprotein, nucleolar, centromere, & topoisomerase 1 antigens
What are the two different types of SS?
What is the clinical presentation of SS?
What are the skin changes in SS?
Shiny, taut skin seen here in a middle-aged woman who has no facial wrinkles at all is typical of scleroderma.
What are the chemically induced SS-like disorders?
- Toxic-oil syndrome
- Vinyl chloride-induced disease
- Bleomycin-induced fibrosis
- Pentazocine-induced fibrosis
- Epoxy & aromatic hydrocarbons-induced fibrosis
- Eosinophilia- myalgia syndrome
SS:
* What are the labs of SS?
* What do you need to watch for?
- ANA is present in 90% with diffuse scleroderma.
- Anticentromere antibody is associated with CREST Syndrome
- Anti-SCL-70 antibody is associated with diffuse scleroderma and has poor prognosis
- Watch for HTN and kidney function decline
* Renal failure, pulmonary fibrosis and/or pulmonary HTN are leading causes of death
SS:
* Cure?
* What is treatment aimmed for?
- No cure
- Treatment is aimed at organ-specific disease processes
* D-penicillamine-controversial benefit to reduce skin thickening & prevent organ involvement
* Glucocorticoids-indicated for inflammatory myositis or pericarditis
* Cyclophosphamide-improves lung function & survival in patients with alveolitis
* Epoprostenol-may improve cardiopulmonary hemodynamics in pts with PHTN
SS Treatment:
* What are PPIs for?
* What are CCBs for?
* What are immunosuppressive drugs for?
- PPIs for GI, ACEI for kidneys, avoidance of triggers
- CCBs for Raynaud’s phenomenon
- Immunosuppressive drugs for pulmonary HTN.
SS prognosis:
* Who has a worst outcome?
* Who has a better prognosis?
* What causes death and morbidity in patients with limited cutaneous disease?
* Prognosis worse in patients with who?
* Death occurs most often from what?
* In patients with diffuse cutaneous disease, what is the survival rate?
* In limited cutaneous disease. what is the survival rate?
- Quite variable; males have a worse prognosis
- Patients with limited cutaneous scleroderma, better prognosis
- Malabsorption syndrome & primary biliary cirrhosis (PBC) causes of death & morbidity in some patients with limited cutaneous disease
- Prognosis worse in patients with diffuse cutaneous disease
- Death occurs most often from pulmonary, cardiac, & renal involvement (CKD)
- In patients with diffuse cutaneous disease, 5-year cumulative survival rate is ~70% & 10-year is ~55%.
- In limited cutaneous disease 5-year is ~90% & 10-year is ~75%.
Systemic lupus erythematosus (SLE):
* Characterized by what?
Autoimmune disorder characterized by inflammation, positive ANA level and involvement of multiple organs
SLE Epidemiology:
* What is the prevalence of SLE?
* Who is it more common in?
* Triple due to why?
* What are estimated incidence rates?
- The reported prevalence of systemic lupus erythematosus (SLE) in the United States is 20 to 150 cases per 100,000.
- 90% women, usually of child-bearing age & more common in African Americans
- Due to improved detection of mild disease, the incidence nearly tripled in the last 40 years of the 20th century.
- Estimated incidence rates are 1 to 25 per 100,000 in North America, South America, Europe, and Asia
SLE:
* What is there a production of?
* Where are immune complexed deposited?
* What does the depositions leads to?
- Production of autoantibodies with specificity for nuclear antigenic determinants leads to immune complex formation.
- Immune complexes deposited in glomeruli, skin, lungs, synovium, mesothelium, & other places.
- Deposition leads to manifestations of disease
What can play a role in SLE?
- Genetics may play a role
- Environmental/diet/ chemical agents/drugs, UV radiation and infections all play a role
What are the typical drugs that cause drug induced lupus?
- INH
- Hydralazine
- Minocycline
- Methyldopa
- Chlorpromazine
- Quinidine
- Procainamide
Drug-Induced lupus:
* What are the clinical features?
* All patients will have what?
* When will the patients improve?
- Clinical features predominantly constitutional, joint, & pleuropericardial
* Rare CNS & renal disease - All patients have antinuclear antibodies(ANA)
- Improvement following withdrawal of offending drug
What is the clinical presentation of SLE?
- Constitutional-fatigue, fever, malaise, weight loss
- Arthritis-inflammatory, symmetric, nonerosive
- Cardiopulmonary- Pericardial effusions & serous pericarditis, myocarditis, Libman- Sacks endocarditis
- Nephritis
- GI-peritonitis, vasculitis
- Cutaneous-rashes-malar “butterfly” rash, photosensitivity, vasculitis, alopecia, oral ulcers
SLE Clinical Presentation, part two
What is the SLE diagnostic criteria?
What labs and levels need to be done for SLE?
- CBC, CMP, Urinalysis, ESR, and Serum complement C3 or C4
- Antibodies of Smith antigen (anti-Smith antibody)
- Anti-Double-stranded DNA (Anti-dsDNA)
- ANA is present in 99%
* But ANA is not specific for SLE - Anti-histone antibodies (present in most JRA/JIA/RA/SLE or even drug induced lupus)
- 50% have + Anticardiolipin Antibody
Anticardiolipin Antibody in SLE:
* How many people have it? What is it associated with?
* How might it manifest?
* How might bleeding may result?
* Confirmation that PTT is prolonged on basis of what?
- Approximately 50% have an anticardiolipin antibody, which is associated with a prolonged PTT & false-positive serologic tests for syphilis.
- This so-called lupus anticoagulant may be manifested by thrombocytopenia, venous or arterial clotting, & recurrent fetal loss
- Although thrombotic problems are most common, if antibody is associated with hypoprothrombinemia, severe thrombocytopenia, or antibodies to clotting factors (usually VIII or IX), bleeding may result.
- Confirmation that PTT is prolonged on basis of a lupus anticoagulant may be proved by failure of normal plasma to correct defect
Clotting ot bleeding issue
What is the SLE treatment?
What is Behcet’s syndrome?
* What is the major risk factor?
Behçet’s syndrome, a recurrent disease of unknown cause, is characterized by painful oral and genital ulcers, eye inflammation, arthritis, central nervous system symptoms, thrombophlebitis/vasculitis, fever, and abdominal symptoms.
* HLA-B51 is a major risk facto
HLA-B27 for AS
- How do you diagnosis behcet’s syndrome?
- What is detected in biopsy?
- (1)Requires the presence of recurrent oral ulcers + 2 of following
* Recurrent genital ulcerations
* Eye lesions
* Skin lesions or a positive pathergy test (inflammatory reactivity to scratches or intradermal saline). - Neutrophil infiltration is detected in biopsy specimens from oral aphthous ulcers and erythema nodosum and pathergy lesions
What is the treatment of Behcet’s treatment?
* What are also signs/symptoms?
Anti-TNF drugs and/or colchicine, dapsone, azathioprine, apremilast, thalidomide, MTX, cyclosporine, biologics like infliximab
Mixed Connective Tissue Disease (MCTD):
* Syndrome characterized by what?
* What is there high titers of?
* Overlap syndromes are what?
- Syndrome characterized by a combination of clinical features seen in SLE, SSC, Polymyositis & RA
- High titers of ANA’s to nuclear ribonucleoprotein (RNP)
- Overlap syndromes are diseases that fulfill diagnostic criteria for two rheumatic diseases.
MCTD:
* What are the clinical manifestations?
MCTD:
* What is the laboratory evaluation?
* What is the treatment?
Laboratory Evaluation
* High-titer ANA’s
* Very high titers of antibody to RNP
* +RF in 50% of pts
Treatment
* Little published data
* Treat based upon manifestations with similar approach to that used if feature occurred in other CTD’s
What is Polyarteritis Nodosa?
* What does it excludes?
* What are unususal findings that should clue into PN?
- Necrotizing vasculitis of medium or small arteries
- Excludes glomerulonephritis or vasculitis in arterioles, capillaries or venules
- Unusual findings, such as infarcts in odd places such as liver or testes, should heighten suspicion
Polyarteritis Nodosa:
* What is the incidence? What can decrease this?
* What is the prevalence?
* What is the etiology?
- Incidence of 0.7/100,000
* Decreased concomitantly with HBV vaccination - Prevalence 50/100,000
- Etiology – HBC/HCV, rarely HIV, parvovirus B19, EBV, deficiency of ADA2 (adenosine deaminase)
What is the PN’s clinical presentation?
PN Diagnosis/imaging:
* What needs to be done?
* What is elevated?
* What is positive and negative
* Urine?
* What might be present sometime?
- What is the PN prognosis if untreated?
- What is death usually from?
- If untreated, prognosis is poor: 10-20% survival rate at 5 years
- Death usually results from gastrointestinal issues (infarcts or perforation) or CV issues (Intractable HTN causing damage across the body)
- What is gout?
- What will go into the synovial fluid?
- Who is affected from gout ?
Gout (monosodium urate [MSU] crystal deposition disease or Podagra) is a systemic disease characterized biochemically by extracellular fluid urate saturation, which is reflected in the blood by hyperuricemia, with serum or plasma urate concentrations exceeding 6.8 mg/dL (approximately 400 micromol/L); this level of urate is the approximate limit of urate solubility.
* Altered purine metabolism and subsequent sodium urate crystal
precipitation into Synovial fluid.
* Seen with patient consuming lots of meat/beer/seafood
1ST MTP JOINT
What are the stages of gout?